Results 291 to 300 of about 105,133 (385)

Trends in novel opioid use and detections in exposures and police drug seizures in New South Wales

open access: yesDrug and Alcohol Review, Volume 45, Issue 1, January 2026.
Abstract Introduction Novel opioids, including non‐medical and non‐opium‐based opioids such as fentanyl analogues and nitazenes, pose a significant risk of harm due to their high potency. There is little published data on novel opioid detections and harms in Australia, yet they are implicated in multiple deaths.
Janette L. Smith   +7 more
wiley   +1 more source

A Scoping Review of the Emergence of Novel Synthetic Opioids in Australian Drug Markets: What Does This Mean for Harm Reduction Responses?

open access: yesDrug and Alcohol Review, Volume 45, Issue 1, January 2026.
ABSTRACT Issues Rising synthetic opioid deaths in North America, and the emergence of nitazene harms has driven concern about novel synthetic opioids (NSO) in Australia. This scoping review aimed to map what is known about NSOs in Australia. Approach Scoping review of peer‐reviewed and grey literature on NSO detections and harms.
Emmanuel Mammoliti   +2 more
wiley   +1 more source

Real‐world use of continuous glucose monitoring in people with type 2 diabetes and chronic kidney disease or on dialysis

open access: yesDiabetic Medicine, Volume 43, Issue 1, January 2026.
Abstract Introduction Continuous glucose monitoring (CGM) has become the standard of care for people with type 1 diabetes (T1D) and some people with type 2 diabetes (T2D). However, there is a lack of data regarding CGM use in people with T2D and chronic kidney disease (CKD), who are at increased risk of hypoglycaemia.
Patrick McGown   +14 more
wiley   +1 more source

A novel framework to assess the prevention value of a health intervention

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 584-592, January 2026.
Abstract Aims Interest in capturing chronic disease prevention impacts on broader economic and societal outcomes is growing; however, this has been challenging to date. We present a comprehensive framework to support assessment of prevention value from a range of stakeholder perspectives, using obesity as an illustrative example.
Jonathan Pearson‐Stuttard   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy